Climb Bio (CLYM)
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated disease...
- Open
- 13.880
- High
- 15.030
- Low
- 13.090
- Prev. Close
- 13.730
- Volume
- 1.97M
- Turnover
- 28.64M
- Avg Price
- 14.520
- Bid/Ask Ratio
- -63.27%
- Amplitude
- 14.13%
- 52wk High
- 18.330
- Volume Ratio
- 1.80
- Turnover Ratio
- 7.07%
Climb Bio Analyst Rating
View moreForecast & Rating
Aug 31, 2026Price forecast
$22.8654.23%
Forecast & RatingStrong buy
14analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 hour ago
Climb Bio executives to speak at Wells Fargo healthcare conference fireside chat
- Market Beat · Aug 27 at 06:40 PM
Climb Bio (NASDAQ:CLYM) Trading Down 6.1% - What's Next?
- Market Beat · Aug 25 at 08:14 AM
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Rating of "Buy" from Analysts
- Tip Ranks · Aug 19 at 09:45 AM
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook
- Simplywall · Aug 18 at 11:39 AM
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story?
- Market Beat · Aug 16 at 07:29 AM
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM
